Topline Results Of Phase 3 Study Indicate Benefit From Prevnar 20 Administered With Seasonal Influenza Vaccine

Infectious Disease Advisor (10/4, Park) reports, “Positive topline results were announced from a phase 3 study evaluating the safety and immunogenicity of Prevnar 20 (pneumococcal 20-valent conjugate vaccine) administered with the seasonal influenza vacci...